Astec LifeSciences Limited (BOM:533138)
India · Delayed Price · Currency is INR 638.90
-10.55 (-1.62%)
At close: Feb 13, 2026
Astec LifeSciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 4,059 | 3,781 | 4,577 | 6,282 | 6,766 | 5,549 |
Other Revenue | 31.57 | 31.57 | 9.41 | 3.31 | 3.34 | 37.96 |
Revenue | 4,091 | 3,813 | 4,586 | 6,285 | 6,769 | 5,587 |
Revenue Growth (YoY) | -1.67% | -16.86% | -27.03% | -7.15% | 21.16% | 5.68% |
Cost of Revenue | 2,703 | 3,056 | 3,249 | 4,069 | 3,920 | 3,457 |
Gross Profit | 1,388 | 757.2 | 1,338 | 2,216 | 2,849 | 2,130 |
Selling, General & Admin | 620.76 | 621.68 | 629 | 533.27 | 513.32 | 394 |
Other Operating Expenses | 848.72 | 797.59 | 762.03 | 911.8 | 788.77 | 582.09 |
Operating Expenses | 1,917 | 1,856 | 1,754 | 1,782 | 1,646 | 1,233 |
Operating Income | -528.89 | -1,099 | -415.94 | 434.56 | 1,203 | 897.14 |
Interest Expense | -365.86 | -362.76 | -248.56 | -201.58 | -86.95 | -42.71 |
Interest & Investment Income | 8.03 | 8.03 | 1.51 | 40.49 | 2.63 | 7.85 |
Currency Exchange Gain (Loss) | 15.9 | 15.9 | 49.71 | 83.92 | 72.45 | 30.4 |
Other Non Operating Income (Expenses) | -22.26 | 1.74 | -3.09 | -3.85 | -0.35 | -4.76 |
EBT Excluding Unusual Items | -893.07 | -1,436 | -616.37 | 353.54 | 1,191 | 887.92 |
Gain (Loss) on Sale of Assets | 20.18 | 20.18 | -1.11 | -5.24 | 0.14 | 2.34 |
Other Unusual Items | -20.94 | - | - | - | - | - |
Pretax Income | -887.61 | -1,410 | -617.48 | 349.47 | 1,211 | 890.71 |
Income Tax Expense | 4.47 | -62.78 | -148.57 | 93.53 | 312.43 | 240.02 |
Earnings From Continuing Operations | -892.08 | -1,347 | -468.91 | 255.94 | 898.83 | 650.69 |
Minority Interest in Earnings | -0.4 | -0.41 | -0.39 | -0.29 | -0.24 | -0.2 |
Net Income | -892.48 | -1,348 | -469.3 | 255.65 | 898.59 | 650.49 |
Net Income to Common | -892.48 | -1,348 | -469.3 | 255.65 | 898.59 | 650.49 |
Net Income Growth | - | - | - | -71.55% | 38.14% | 36.91% |
Shares Outstanding (Basic) | 21 | 20 | 20 | 20 | 20 | 20 |
Shares Outstanding (Diluted) | 21 | 20 | 20 | 20 | 20 | 20 |
Shares Change (YoY) | 5.75% | 0.01% | 0.02% | 0.04% | 0.05% | 0.09% |
EPS (Basic) | -43.02 | -68.71 | -23.93 | 13.04 | 45.87 | 33.23 |
EPS (Diluted) | -43.02 | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 |
EPS Growth | - | - | - | -71.56% | 38.06% | 36.84% |
Free Cash Flow | - | -302.21 | -1,253 | -426.03 | -803.74 | -1,107 |
Free Cash Flow Per Share | - | -15.41 | -63.88 | -21.73 | -41.01 | -56.50 |
Dividend Per Share | - | - | 1.500 | 1.500 | 1.500 | 1.500 |
Gross Margin | 33.93% | 19.86% | 29.17% | 35.26% | 42.09% | 38.12% |
Operating Margin | -12.93% | -28.83% | -9.07% | 6.91% | 17.78% | 16.06% |
Profit Margin | -21.82% | -35.34% | -10.23% | 4.07% | 13.28% | 11.64% |
Free Cash Flow Margin | - | -7.93% | -27.32% | -6.78% | -11.87% | -19.81% |
EBITDA | -43.7 | -670.07 | -61.53 | 759.35 | 1,536 | 1,146 |
EBITDA Margin | -1.07% | -17.57% | -1.34% | 12.08% | 22.70% | 20.51% |
D&A For EBITDA | 485.19 | 429.14 | 354.41 | 324.79 | 332.88 | 248.47 |
EBIT | -528.89 | -1,099 | -415.94 | 434.56 | 1,203 | 897.14 |
EBIT Margin | -12.93% | -28.83% | -9.07% | 6.91% | 17.78% | 16.06% |
Effective Tax Rate | - | - | - | 26.76% | 25.79% | 26.95% |
Revenue as Reported | 4,123 | 3,869 | 4,638 | 6,412 | 6,870 | 5,628 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.